Petros Pharma Files 2023 Annual Report Amendment

TL;DR

Petros Pharma amended its 2023 10-K, check for updates on their financials.

AI Summary

Petros Pharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing, dated May 31, 2024, provides updated information for the company, which is incorporated in Delaware and operates in the pharmaceutical preparations industry. The company's principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, NY.

Why It Matters

This amendment provides updated financial and operational information for Petros Pharmaceuticals, Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an amendment to its annual report, there could be material updates that impact its financial health or operational status.

Key Players & Entities

• Petros Pharmaceuticals, Inc. (company) — Registrant
• 2023 (date) — Fiscal Year End
• May 31, 2024 (date) — Filing Date
• Delaware (location) — State of Incorporation
• 1185 Avenue of the Americas, 3rd Floor, New York, NY (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke

Filing Documents

• tm2416176d1_10ka.htm (10-K/A) — 65KB
• tm2416176d1_ex23-1.htm (EX-23.1) — 2KB
• tm2416176d1_ex23-2.htm (EX-23.2) — 3KB
• tm2416176d1_ex31-1.htm (EX-31.1) — 3KB
• tm2416176d1_ex31-2.htm (EX-31.2) — 3KB
• tm2416176d1_ex32.htm (EX-32) — 5KB
• 0001104659-24-067284.txt ( ) — 308KB
• ptpi-20231231.xsd (EX-101.SCH) — 3KB
• ptpi-20231231_lab.xml (EX-101.LAB) — 36KB
• ptpi-20231231_pre.xml (EX-101.PRE) — 24KB
• tm2416176d1_10ka_htm.xml (XML) — 7KB

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)(1) Financial Statements No financial statements are filed with this Amendment No. 1. These items were included as part of the Original Form 10-K. (a)(2) Financial Statements Schedule None. (a)(3) Exhibits Index to Exhibits Exhibit No. Description 2.1 Agreement and Plan of Merger and Reorganization, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc., Neurotrope, Inc., PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC (incorporated by reference to Exhibit 2.1 to the Company's Registration Statement on Form S-4 filed on October 28, 2020). 2.2 First Amendment to Agreement and Plan of Merger, dated as of July 23, 2020, by and between Petros Pharmaceuticals, Inc., PM Merger Sub 1, LLC, PN Merger Sub 2, Inc., Neurotrope, Inc. and Metuchen Pharmaceuticals LLC (incorporated by reference to Exhibit 2.2 to the Company's Registration Statement on Form S-4 filed on October 28, 2020). 2.3 Second Amendment to Agreement and Plan of Merger, dated as of September 30, 2020, by and between Petros Pharmaceuticals, Inc., PM Merger Sub 1, LLC, PN Merger Sub 2, Inc., Neurotrope, Inc. and Metuchen Pharmaceuticals LLC (incorporated by reference to Exhibit 2.3 to the Company's Registration Statement on Form S-4 filed on October 28, 2020). 3.1 Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 2, 2020). 3.2 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on November 30, 2022). 3.3 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8 - K filed on September 15, 2023).

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PETROS PHARMACEUTICALS, INC. May 31, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer

View Full Filing

View this 10-K/A filing on SEC EDGAR